Physician profile
David Scott Weiss
NPI 1861493116
$12,871.32
in general payments reported to CMS, 2019-2025
40 companies · $2,944 in 2025
The $2,944 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,092 · 2020: $411 · 2021: $418 · 2022: $2,142 · 2023: $3,544 · 2024: $2,321 · 2025: $2,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,749 · Consulting Fee: $2,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,748.73 |
| Consulting Fee | $2,060.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation | $3,090.00 | 2022-2023 | Evis Exera III Video System Center |
| Abbvie INC. | $2,187.93 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $860.26 | 2023-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $711.36 | 2019-2025 | Xifaxan, Plenvu |
| Genzyme Corporation | $697.26 | 2022-2025 | |
| Madrigal Pharmaceuticals | $670.88 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $522.30 | 2021-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $452.05 | 2019-2025 | Entyvio |
| Celgene Corporation | $425.06 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $391.63 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $390.91 | 2023-2025 | Omvoh, Mounjaro |
| Intercept Pharmaceuticals, INC. | $376.11 | 2019-2025 | Ocaliva |
| Celltrion USA INC. | $270.51 | 2024-2025 | Vegzelma |
| Ardelyx, INC. | $204.38 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $168.56 | 2022-2025 | Dupixent |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $167.92 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $143.83 | 2019-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $140.76 | 2021-2025 | Reblozyl |
| Ferring Pharmaceuticals INC. | $113.35 | 2022-2025 | Rebyota, Clenpiq |
| Daiichi Sankyo INC. | $95.36 | 2019-2020 | |
| Braintree Laboratories, INC. | $90.84 | 2022-2025 | Suflave, Sutab |
| Shionogi INC | $74.82 | 2019 | |
| Aimmune Therapeutics, INC. | $67.62 | 2023-2025 | Zenpep |
| Redhill Biopharma INC. | $55.54 | 2021-2022 | |
| Ucb, INC. | $54.44 | 2019 | |
| Pfizer INC. | $46.38 | 2021-2024 | |
| Novo Nordisk INC | $43.86 | 2025 | Wegovy |
| Exact Sciences Corporation | $43.45 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $42.38 | 2019 | |
| Alfasigma USA, INC. | $38.80 | 2020 | |
| Allergan, INC. | $34.98 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $34.60 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $27.31 | 2023 | Bylvay |
| Amgen INC. | $25.22 | 2020 | |
| Vivus LLC | $22.93 | 2025 | Pancreaze |
| Janssen Scientific Affairs, LLC | $22.08 | 2025 | Tremfya |
| Glaxosmithkline, LLC. | $21.82 | 2022 | |
| Nestle Healthcare Nutrition INC. | $21.26 | 2021 | |
| Evoke Pharma, INC. | $19.75 | 2024 | |
| Romark Laboratories, Lc | $2.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.